Clinical and epidemiological data for bone metastases

被引：1
作者：
Debiais, F. [1 ]
机构：
[1] Univ Poitiers, CHU Poitiers, Serv Rhumatol, F-86021 Poitiers, France
来源：
ONCOLOGIE | 2015年 / 17卷 / 03期
关键词：
Bone metastasis; Epidemiology; Skeletal-related events; SKELETAL-RELATED EVENTS; BREAST-CANCER PATIENTS; LONG-TERM EFFICACY; PROGNOSTIC-FACTORS; ZOLEDRONIC ACID; SOLID TUMORS; COMPLICATIONS; MORTALITY; SURVIVAL; CARCINOMA;
D O I：
10.1007/s10269-015-2488-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bone is a frequent site for metastases in patients with advanced solid tumours, above all concerning prostate, breast, and lung cancers. Bone metastases are often responsible for pain and can be at the origin of skeletal-related events (SRE), associated with morbidity, decrease in quality of life and survival, highlighting the importance of a rapid diagnosis of cancer and treatment in case of bone metastases so as to decrease the risk of these complications.
引用
收藏
页码：63 / 68
页数：6
相关论文
共 50 条
  • [21] Implications of Bone Metastases and the Benefits of Bone-Targeted Therapy
    Lipton, Allan
    SEMINARS IN ONCOLOGY, 2010, 37 (05) : S15 - S29
  • [22] Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States
    Hernandez, Rohini K.
    Adhia, Avanti
    Wade, Sally W.
    O'Connor, Emily
    Arellano, Jorge
    Francis, Kevin
    Alvrtsyan, Hasmik
    Million, Ryan P.
    Liede, Alexander
    CLINICAL EPIDEMIOLOGY, 2015, 7 : 335 - 345
  • [23] Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice
    Cives, Mauro
    Pelle, Eleonora
    Rinzivillo, Maria
    Prosperi, Daniela
    Tucci, Marco
    Silvestris, Franco
    Panzuto, Francesco
    NEUROENDOCRINOLOGY, 2021, 111 (03) : 207 - 216
  • [24] Clinical Significance of Bone Metastases in Pleural Mesothelioma
    Miyake, Mitsutomi
    Kuribayashi, Kozo
    Doi, Hiroshi
    Kubota, Aki
    Otuski, Taiichiro
    Negi, Yoshiki
    Mikami, Koji
    Takahashi, Ryo
    Nakamura, Akifumi
    Nakajima, Yasuhiro
    Fujimoto, Daichi
    Kitajima, Kazuhiro
    Minami, Toshiyuki
    Kijima, Takashi
    THORACIC CANCER, 2025, 16 (05)
  • [25] Inhibition of RANK Ligand to treat bone metastases
    Body, Jean-Jacques
    BULLETIN DU CANCER, 2013, 100 (11) : 1207 - 1213
  • [26] Management of bone metastases in prostate cancer: a review
    Bienz, Marc
    Saad, Fred
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2015, 9 (03) : 261 - 267
  • [27] Treatment of bone metastases before the onset of pain
    Costa, Luis
    Lipton, Allan
    Hadji, Peyman
    Chen, Yin-Miao
    Kosmidis, Paris
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (03) : 531 - 538
  • [28] Progress in the treatment of bone metastases in cancer patients
    Mackiewicz-Wysocka, Malgorzata
    Pankowska, Magdalena
    Wysocki, Piotr J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (06) : 785 - 795
  • [29] All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma
    Brozovich, Ava
    Garmezy, Benjamin
    Pan, Tianhong
    Wang, Liyun
    Farach-Carson, Mary C.
    Satcher, Robert L.
    JOURNAL OF BONE ONCOLOGY, 2021, 31
  • [30] Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss
    Dionisio, Maria Rita
    Mansinho, Andre
    Abreu, Catarina
    Cavaco-Silva, Joana
    Casimiro, Sandra
    Costa, Luis
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (06) : 1114 - 1124
12345